On Friday, Arcutis Biotherapeutics Inc (NASDAQ: ARQT) opened lower -4.61% from the last session, before settling in for the closing price of $13.67. Price fluctuations for ARQT have ranged from $6.99 to $17.75 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 52.27% at the time writing. With a float of $104.82 million, this company’s outstanding shares have now reached $119.14 million.
Let’s determine the extent of company efficiency that accounts for 342 employees. In terms of profitability, gross margin is 88.39%, operating margin of -57.0%, and the pretax margin is -60.67%.
Arcutis Biotherapeutics Inc (ARQT) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Arcutis Biotherapeutics Inc is 12.06%, while institutional ownership is 98.79%. The most recent insider transaction that took place on May 28 ’25, was worth 24,807. In this transaction an insider of this company sold 1,800 shares at a rate of $13.78, taking the stock ownership to the 202,599 shares. Before that another transaction happened on May 28 ’25, when Company’s Officer proposed sale 1,800 for $13.78, making the entire transaction worth $24,807.
Arcutis Biotherapeutics Inc (ARQT) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 52.27% per share during the next fiscal year.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Trading Performance Indicators
Check out the current performance indicators for Arcutis Biotherapeutics Inc (ARQT). In the past quarter, the stock posted a quick ratio of 3.37. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.30.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.04, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach 0.16 in one year’s time.
Technical Analysis of Arcutis Biotherapeutics Inc (ARQT)
Looking closely at Arcutis Biotherapeutics Inc (NASDAQ: ARQT), its last 5-days average volume was 1.97 million, which is a drop from its year-to-date volume of 2.32 million. As of the previous 9 days, the stock’s Stochastic %D was 19.56%. Additionally, its Average True Range was 0.83.
During the past 100 days, Arcutis Biotherapeutics Inc’s (ARQT) raw stochastic average was set at 28.85%, which indicates a significant increase from 10.94% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 53.09% in the past 14 days, which was lower than the 73.03% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.50, while its 200-day Moving Average is $12.38. However, in the short run, Arcutis Biotherapeutics Inc’s stock first resistance to watch stands at $13.45. Second resistance stands at $13.86. The third major resistance level sits at $14.17. If the price goes on to break the first support level at $12.73, it is likely to go to the next support level at $12.42. Should the price break the second support level, the third support level stands at $12.01.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Key Stats
There are currently 119,202K shares outstanding in the company with a market cap of 1.55 billion. Presently, the company’s annual sales total 196,540 K according to its annual income of -140,040 K. Last quarter, the company’s sales amounted to 65,850 K and its income totaled -25,060 K.
